[Activation of endogenous nucleases as affected by sodium arsenate and cisplatin].
Screening of pharmaceutical agents releasing active nucleases from inactive complexes was performed. Cisplatin and sodium arsenate were shown in vitro to have such properties. Sodium arsenate which is more expedient for the treatment of human patients was studied in vivo. It was administered to albino mice in a dose of 0.2 mg/kg once a day for 6 days. Due to the release, the activity of free serum DNAse and RNAse markedly increased (1.5-2 times). Activation of endogenic nucleases is more promising than the use of exogenic enzymes in complex therapy of viral affections and rickettsiosis.
Maksimovich
M B
MB
Kushnir
Z G
ZG
D000818:Animals; D001149:Arsenates / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D003851:Deoxyribonucleases / Q000097:blood / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000378:metabolism; D006168:Guinea Pigs; D066298:In Vitro Techniques; D051379:Mice; D012260:Ribonucleases / Q000097:blood / Q000378:metabolism*
D001149:Arsenates; D004791:Enzyme Inhibitors; C009277:sodium arsenate; D003851:Deoxyribonucleases; D012260:Ribonucleases; D002945:Cisplatin